New daily shot could curb appetite in obesity

NCT ID NCT06621017

Completed Disease control Sponsor: Rose Pharma Inc Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 2 trial tested whether a daily injection of ROSE-010, a GLP-1 analogue, can reduce appetite and food intake in 40 overweight or obese women. Participants received either a low or high dose of ROSE-010 or a placebo, and researchers measured how much they ate at lunch and how hungry they felt. The goal is to find a new treatment option for weight management.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ROSE-010 (a GLP-1 analogue similar to drugs like semaglutide)
What this could lead to: If successful, this could point toward a new daily injection to help control appetite and reduce food intake in people with overweight or obesity.
What could go wrong: This is a small, early-phase trial with only 40 women, so results may not apply to everyone. The drug may cause side effects or fail to show meaningful weight loss.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Anorexia Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY & OVERWEIGHT

Contacts and locations

Show contact details

Locations

Medpace Clinical Pharmacology

Cincinnati, Ohio, 45227, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.